I hear a version of the same sentence constantly in consultations with patients: "I thought I was the only one this was happening to." A 2022 study of 178 postmenopausal women puts a number on that feeling. Researchers found measurable female pattern hair loss in 52.2% of them. Over half. Whatever is happening in the mirror right now, at whatever stage of this transition, the odds say it's shared by more women than not.

The mechanism behind it traces to a 2025 review in the journal Maturitas, and everything cited below comes from peer-reviewed sources on PubMed rather than the usual wellness-blog paraphrasing. Some of the research has real limits, particularly around treatment specifically for postmenopausal women, and I'd rather flag those limits directly than smooth them over.

The Hormones Involved

Hair follicles carry estrogen receptors. That fact alone explains why menopause touches hair at all: the follicle is literally built to respond to estrogen levels, the same way skin and bone tissue elsewhere in the body respond to it, and the same way it responds to androgens. Ovarian estrogen production falls sharply during the menopausal transition, and that fall can start a full decade before a woman's actual last period.

Testosterone doesn't necessarily go up during this window, and that distinction trips people up constantly. Researchers describe what happens instead as relative androgen excess: estrogen drops faster than androgens do, so androgens end up proportionally stronger even without rising in absolute terms. Two consequences follow. Testosterone converts more freely into DHT, the androgen that shrinks genetically sensitive follicles. And estrogen's separate job, dilating blood vessels, weakens too, cutting into blood flow the scalp used to get.

Progesterone rarely makes it into these explanations, which is a gap worth closing. It counterbalances estrogen and independently blunts some of androgen's effects on the follicle. Its decline runs on its own timeline, separate from estrogen's, which means three hormones are shifting here, not one.

The hair growth cycle itself gets caught in the middle of all this. Each follicle normally spends years in an active growth phase called anagen. A brief transitional phase follows. Then comes a resting phase, where the hair eventually sheds. Falling estrogen shortens that anagen window. More follicles land in the resting phase at once as a result, which is why shedding can feel like it accelerates over a matter of months rather than creeping up gradually. The follicle isn't dying in most cases. It's cycling faster and producing thinner output each time around.

The Years Before Menopause Actually Matter

A woman in her 40s who mentions thinning hair to a doctor gets dismissed more often than she should. Stress, she's told, or nothing at all. Perimenopause runs four to eight years on average before a final period, and hair follicles start responding to falling estrogen well before that final period arrives. Prevalence data backs this up with an odd detail: FPHL actually peaks twice, once between 25 and 40 for mostly genetic reasons, and again between 50 and 60, tied specifically to the menopausal transition. Delayed diagnosis is common enough in this age group to name outright, and the delay itself has a cost: earlier intervention generally means more follicles are still salvageable rather than already miniaturized past the point where treatment does much.

Recognizing It

FPHL during menopause has a specific look. Density drops first at the part line and crown, spreading outward while the front hairline typically holds. Dermatologists call this the Ludwig pattern, distinct from the receding hairline men usually get. It's also distinct from telogen effluvium, a different condition entirely, one involving sudden, diffuse shedding across the whole scalp rather than gradual thinning in specific zones. Both can happen around menopause. Sometimes both happen together, and that overlap is exactly why a real diagnosis matters more than a guess in the mirror.

Most cases stay mild. Among the 178 women in that same study, 73.2% had mild FPHL. Moderate cases came in at 22.6%. Advanced cases were rare, just 4.3%. Low self-esteem told a different story, though. It showed up in 60% of the women in that study, and it got more common as severity increased.

A few practical tells show up before the mirror confirms anything. The part looks wider than it used to. A ponytail feels thinner in the hand. Scalp shows through more under bright light, especially at the crown. Texture shifts too, often toward finer or more brittle. A haircut takes longer to grow back than it once did. And a sudden jump in shedding, in the shower drain or on a brush, counts as its own signal, particularly when it's a clear jump from a normal baseline rather than a gradual change. None of these confirm menopause specifically on their own, since thyroid problems and nutrient gaps mimic several of them, but two or three together are worth an actual appointment rather than a wait-and-see approach.

A trichoscopy exam, essentially a magnified look at the scalp and individual follicles, is how dermatologists actually confirm FPHL rather than relying on a patient's own description of what she's noticed. It can distinguish miniaturized follicles, the hallmark of pattern hair loss, from the more uniform shedding pattern seen in telogen effluvium, which matters because the two conditions sometimes call for different approaches even when they look similar day to day.

What Else Could Be Going On

Hormones rarely act alone here. In the same 178-woman study, a BMI of 25 or above roughly doubled the odds of FPHL, even controlling for age and family history. Thyroid imbalance runs on its own separate timeline, one that happens to overlap with menopause. It drives shedding independently of estrogen or androgen levels. A simple TSH blood test is often part of a proper workup for exactly that reason, not as an afterthought. Family history matters on a separate track too, genetics that has nothing to do with hormones directly, and a mother or sister with noticeable thinning is a meaningful data point worth mentioning to a doctor. Deficiencies in iron, zinc, B12, or vitamin D can each undercut follicle health regardless of what hormones are doing.

Stress deserves its own line item, separate from the hormonal picture entirely. Menopause tends to land during a genuinely stressful stretch of life, caregiving, career pressure, disrupted sleep from night sweats, and chronic stress can trigger telogen effluvium on its own, layered right on top of whatever hormones are already doing. Sleep loss compounds this further, since poor sleep raises cortisol, and elevated cortisol has its own independent effect on the hair cycle separate from anything estrogen or androgen related. Two women with identical symptoms can be dealing with entirely different root causes, or several overlapping ones at once.

The Current State of Treatment

Minoxidil has the deepest evidence base of anything discussed here, an FDA-approved topical sold over the counter at 2% for women. Results generally take three to six months, and stopping the product reverses whatever ground was gained. A minority of users deal with an initial shedding phase or scalp irritation in the first several weeks, which typically resolves rather than signaling the product isn't working. Finasteride and dutasteride get prescribed off-label for postmenopausal women in real clinical practice. The Maturitas review is candid about a gap here, though: large, randomized trials specifically in this population don't really exist yet. Prescribing leans on evidence from broader alopecia research instead of dedicated data as a result. Laser therapy, PRP injections, and hair transplants round out the current options. Each carries its own cost and evidence profile, and each requires a bigger upfront commitment than a topical bottle does.

None of it targets root cause automatically. Someone whose thinning traces back to a thyroid problem won't see much from minoxidil, no matter how well-studied minoxidil is for hormonal cases specifically. That mismatch, generic treatment against an unidentified cause, is where a lot of women end up stuck cycling through products that were never built for their actual situation.

Where Personalization Comes In

MDhair starts from an AI scalp assessment rather than a default formula, identifying which factor, hormonal, nutritional, genetic, some mix of the three, is actually most likely driving a given case. A quiz plus a scalp photo feed that assessment, and the recommendation shifts based on what comes back rather than assuming every woman past 50 has the same hormonal story. The hormonal formula specifically targets the estrogen and androgen mechanisms described above, bundled with a supplement and dermatologist access rather than sold alone. Ongoing check-ins matter here too, since a woman's hormonal picture keeps shifting through perimenopause and into full menopause, and a regimen that fit at the start of that transition may need adjusting a year or two later.

I ran the underlying trial myself, six months, IRB-approved, on MDhair's personalized regimens. Hair growth came in at roughly 2.8 times a leading supplement competitor. Hair quality landed around 3.0 times that same competitor. Both numbers held at p<0.01. Scanning electron microscopy tracked something separate from those growth figures: hair-strand cuticle damage improving from Grade 2, visible cracking, down to Grade 0, smooth and intact, across the same six months. That's evidence for a matched, multi-part routine specifically, not a claim that one ingredient handles menopausal hair loss by itself.

What's Actually Regulated Here

Minoxidil is the only genuine drug in this discussion, cleared narrowly for mild-to-moderate androgenetic hair loss rather than menopause as a diagnosis. Finasteride and dutasteride are prescription drugs too, just used outside their original approved indication in this specific population. Everything else, supplements, serums, cosmetic formulations, sits outside FDA drug evaluation entirely and isn't meant to diagnose, treat, cure, or prevent disease on its own, regardless of how confidently a label reads.

Blood work, not guesswork, is what actually rules a thyroid or nutrient cause in or out, so a doctor's visit belongs at the start of this process rather than the end. Pregnancy, nursing, or an existing condition are reasons to loop a doctor in before starting anything new. Irritation from a topical product means stopping and reassessing, not pushing through.

The Takeaway

This transition explains the shedding. That's the first thing worth sitting with, since it means losing hair during perimenopause or menopause isn't a personal failing or an unexplained mystery, even in the places where the treatment research still lags behind the science of why it happens. The harder, more useful question is which factor is actually driving a specific case, hormonal, nutritional, genetic, thyroid, since the same visible symptom can trace back to entirely different roots in two different women.

A blood panel settles the thyroid and nutrient questions within weeks. A scalp assessment settles whether hormones are the real driver at all. Neither takes long, and over half of postmenopausal women deal with some version of this experience, so there's no reason to sit with it in silence waiting to see if it resolves on its own. That's the starting point MDhair was actually built around.

Dr. Yoram Harth is a board-certified dermatologist and Co-Founder and Chief Medical Officer of MDalgorithms Inc., the company behind MDhair and MDacne. A magna cum laude graduate of Tel Aviv University's Sackler School of Medicine, he trained in dermatology at Rambam Medical Center and completed a research fellowship at Columbia-Presbyterian Medical Center in New York. His work spans phototherapy, photodynamic therapy, and AI-personalized skin and hair care.

Sources

1. Bhardwaj V, Rodgers N, Harth O, Harth Y. Artificial Intelligence-Based Personalization of Treatment Regimen for Hair Loss: A 6-Month Clinical Trial. J Drugs Dermatol. 2025;24(3):233-238. doi:10.36849/JDD.8611

2. Gupta AK, Economopoulos V, Mann A, Wang T, Mirmirani P. Menopause and hair loss in women: exploring the hormonal transition. Maturitas. 2025;198:108378. doi:10.1016/j.maturitas.2025.108378

3. Chaikittisilpa S, Rattanasirisin N, Panchaprateep R, et al. Prevalence of female pattern hair loss in postmenopausal women: a cross-sectional study. Menopause. 2022;29(4):415-420. doi:10.1097/GME.000000000000192

Find the most effective hair growth products for you by taking the free hair assessment.